Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 29, 2007

View Archived Issues

Effect of paliperidone on QTc interval not clinically relevant

New anti-HCV drugs described in recent Bayer patent

New agents for inflammatory disorders reported in recent patents

AGI-003 effective in non-constipated irritable bowel syndrome

Three-year results show benefit of alemtuzumab treatment for multiple sclerosis

STEALTH I, BEACON and CREATE trials show positive results for BioMatrix and Excel

Combination therapy with quetiapine effective in bipolar disorder

Recent patents disclose novel analgesic agents

Marillion initiates phase I human clinical trial for anticancer drug MN-201

Vitor will undergo pilot phase III trial in order to finalize special protocol assessment

NPS Pharmaceuticals receives Japanese approval for cinacalcet hydrochloride

Positive results from phase II clinical trial of Anthera's A-002 for cardiovascular disease

Primary endpoint met in phase III Treanda trial for indolent NHL

Statistical significance in primary endpoints reported for EVT-201 in phase II

First human DISP1 gene mutation in a patient with congenital diaphragmatic hernia

In vivo efficacy of cell adhesion inhibitor K-13182 in Sjogren's syndrome mouse model

New ghrelin receptor antagonists with potential for the treatment of diabetes and obesity

Tolerx forms alliance with GlaxoSmithKline to develop and commercialize TRX-4

Daiichi Sankyo and Lilly suspend two phase II trials of antiplatelet agent prasugrel

Argenta extends integrated contract drug discovery agreement with Genentech

Ipsat reveals positive results from phase IIb study of Ipsat P1A

Galapagos and Janssen enter into global alliance on rheumatoid arthritis research

Yale Cancer Center begins clinical trial of Marshall Edwards' oral phenoxodiol

Gene expression patterns in white blood cells associated with multiple sclerosis are identified

Omrix initiates phase I/II clinical trial of Adhexil in gynecological surgery of the ovaries

Callisto initiates phase II extension trial of atiprimod for neuroendocrine cancer

Osiris begins phase II study of Prochymal for type 1 diabetes

Haemacure adopts new two-phase strategy in clinical trials for Hemaseel HMN

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 31, 2026.
AIDS 2026: New targets for metabolic dysfunction despite ART
BioWorld
Although antiretroviral therapy (ART) can suppress HIV to undetectable levels, a growing body of evidence suggests that the virus leaves a lasting biological...
Jingxin discloses new muscarinic and sigma receptor agonists
BioWorld Science
Shanghai Jingxin Biopharmaceutical Co. Ltd. and Zhejiang Jingxin Pharmaceutical Co. Ltd. have synthesized new muscarinic acetylcholine receptor and sigma receptor...
Tuojie Biotech (Shanghai) synthesizes new SARM1 inhibitors
BioWorld Science
Tuojie Biotech (Shanghai) Co. Ltd. has prepared and tested NAD(+) hydrolase SARM1 (SAMD2; MyD88-5) inhibitors found to be potentially useful for the treatment of...
Death in Chinese gene-editing trial exposes ethical fault lines
BioWorld
The death of a 6-year-old girl after receiving an experimental brain-directed gene-editing therapy at the Xinhua Hospital in Shanghai has reopened debate over how...